{"name": "Apellis Pharmaceuticals",
 "permalink": "apellis-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/apellis-pharmaceuticals",
 "homepage_url": "http://www.apellis.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": 6,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": null,
 "email_address": "",
 "phone_number": "",
 "description": "",
 "created_at": "Fri Apr 12 18:13:51 UTC 2013",
 "updated_at": "Thu May 30 05:38:09 UTC 2013",
 "overview": "\u003Cp\u003EApellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia\u2019s family of complement inhibitors.  Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.\u003C/p\u003E",
 "image": null,
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$10M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "",
    "source_description": "",
    "raised_amount": 10000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": null,
    "funded_day": null,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}